Clinical Trial Update: A Feasibility and Safety Study of Vaccination With Poly-ICLC and Peptide-pulsed Dendritic Cells in Patients With Metastatic, Locally Advanced, Unresectable, or Recurrent Pancreatic Adenocarcinoma [Phase 1]

View source ↗

Summary

Phase 1 feasibility and safety study evaluating vaccination with Poly-ICLC and peptide-pulsed dendritic cells in patients with metastatic or unresectable pancre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Peptide-pulsed dendritic cell vaccine (peptide-pulsed dendritic cell vaccine)
• Poly-ICLC (poly-ICLC)

Snippet

Sponsor: Carolyn Britten | Conditions: Metastatic Pancreatic Cancer | Phase 1 | Status: COMPLETED